Author: John Pinching

Financing and global licensing deal to accelerate phase 2b development of AP306

Collaboration aims to streamline and scale next‑generation Treg therapy production

Study to assess oral therapy for patients with inadequate response to TNF inhibitors

Phase 3 trial delivers significant skin clearance and symptom improvement

Regulator authorises deuruxolitinib for adults with extensive hair loss